Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Inhaled KB707 in Solid tumor/s, Lung Metastases, Cancer. The expected timing is based on the latest available company guidance and may change.
KYANITE-1 study. 4/22/24- First patient dosed. 12/18/24- Announced early evidence of monotherapy activity. 5/6/25- Present clinical update at ASCO'25 on June 2, 2025. 8/21/25- Prioritized development. Ongoing enrollment. 11/03/25:- New KYANITE-1 cohort opens; expect interim efficacy data and registrational Ph3 plans in H2 2026. 02/17/26:- FDA RMAT for advanced NSCLC; KYANITE-1 NSCLC combo cohort enrolling; interim efficacy and registrational plans expected in 2026. 05/04/26:- KYANITE-1 NSCLC combo cohort enrolling; still expect interim efficacy data and registrational plans later in 2026. 08/03/26:- KYANITE-1 ASCO results showed 31% ORR; updated interim results expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.